How Ovarian Cancer Treatment Is Planned: Surgery, Chemotherapy and the Order They Come In

The consultation room is quiet except for the scratch of a pen. The surgeon is drawing: two small ovals, a larger shape between them, then a loose cloud of dots across the page. “This is what we saw on the scan,” she says. “Now let’s talk about what happens next, and in what order.” The woman across the desk has one question, and it is not really about drawings. It is about whether the plan has a shape she can hold on to.

It does. Ovarian cancer treatment by stage follows a logic that oncologists have refined over decades, and once the logic is visible, the appointments, scans and blood tests stop feeling random. Two tools do most of the work, surgery and chemotherapy, and the real decisions are about how much of each, and which comes first.

This article walks through that logic stage by stage, explains what actually happens in the operating room and the infusion chair, and is honest about what the evidence can and cannot tell you.

What does "ovarian cancer treatment by stage" actually mean?

Stage is a shorthand for how far the cancer has traveled from where it began. For ovarian cancer, doctors use a four-stage system from the International Federation of Gynecology and Obstetrics, usually written in Roman numerals, and the National Cancer Institute’s treatment summary follows the same scheme.

Stage 1 means the cancer is limited to one or both ovaries or fallopian tubes. Stage 2 means it has spread within the pelvis, for example to the uterus or the lining of the pelvic wall. Stage 3 means it has reached the lining of the abdomen (the peritoneum, a thin membrane covering the abdominal organs) or nearby lymph nodes. Stage 4 means it has spread further, to fluid around the lungs, to organs such as the liver’s interior, or beyond the abdomen entirely.

Why does this shape treatment so heavily? Because ovarian cancer spreads in an unusual way. Rather than traveling mainly through the bloodstream, it tends to shed cells that float in abdominal fluid and settle on nearby surfaces, like seeds scattered across a garden bed. That pattern is why surgeons think in terms of “visible disease” across the whole abdomen, and why chemotherapy that circulates everywhere matters so much once cells have escaped the ovary.

Stage is only half of the picture, though. The other half is the cancer’s type and grade. Most ovarian cancers are epithelial, meaning they arise from the cells on the surface of the ovary or fallopian tube; rarer germ cell and stromal tumors behave differently and are planned separately. Grade describes how abnormal the cells look under a microscope, and a low-grade stage 1 tumor may be treated very differently from a high-grade one of the same size. When your team describes your cancer, ask for all three words: stage, type and grade. Together they explain almost every decision that follows.

How is ovarian cancer staged, and why is surgery often the staging test?

Here is something that surprises many people: the stage written in your notes is often not final until after an operation. Scans, a pelvic examination and a blood test for CA-125 (a protein that is raised in many, though not all, ovarian cancers) give a provisional picture. The definitive stage comes from what the surgeon sees and what the pathologist finds in the tissue removed.

The reason is physical. A CT scan can miss tiny deposits on the peritoneum that a surgeon can see or feel directly. So for many people, the first operation does two jobs at once: it removes the cancer and it establishes exactly how far the cancer had spread. The National Cancer Institute’s treatment summary describes this surgical staging as a standard part of care for epithelial ovarian cancer.

During a staging operation the surgeon typically removes the ovaries and fallopian tubes, the uterus, the omentum (a fatty apron of tissue hanging over the intestines where floating cancer cells often settle), and samples of lymph nodes and peritoneal surfaces. Fluid from the abdomen is collected and examined for cancer cells. Each of these findings can move the stage up or down.

This is also why treatment plans are frequently described as provisional at the first appointment. A team may say “we think this is stage 1 or 2, and we will confirm after surgery.” That is not indecision; it is honesty about what imaging can and cannot show.

Not everyone follows this path. When scans clearly show widespread disease, or when someone is not well enough for major surgery, a biopsy (a small tissue sample taken with a needle or through a small incision) may confirm the diagnosis instead, and chemotherapy may begin before any large operation. That choice, discussed later in this article, is one of the most important forks in the whole pathway.

Stage 1 ovarian cancer treatment: who gets less extensive surgery, and who is asked to wait

Stage 1 is where treatment plans vary most from person to person, because the cancer has not left the ovary and there is genuine room for judgment.

For most people with stage 1 disease, the standard operation is the full staging surgery described above. If the pathology then shows a low-grade tumor confined to one ovary with no cancer cells in abdominal fluid, surgery alone may be considered enough, with regular follow-up rather than chemotherapy. The National Cancer Institute’s summary notes that chemotherapy after surgery is generally reserved for stage 1 cancers with higher-risk features, such as high grade, a ruptured tumor or cancer on the ovary’s surface.

Two groups are commonly offered a modified approach:

• People who hope to have children. When the cancer appears limited to one ovary and is low grade, a surgeon may remove only the affected ovary and tube, leaving the uterus and other ovary in place. This fertility-sparing surgery still includes careful staging of the abdomen. The trade-off, which the team will explain plainly, is that some cancer risk remains in the tissue left behind, and closer monitoring is needed.
• People with borderline or very low-grade tumors. Some ovarian tumors sit on the boundary between benign and malignant. Many of these are treated with surgery alone and observation.

Who is asked to wait? Occasionally, someone with an early tumor discovered incidentally during another operation will be asked to hold off on further treatment until a specialist gynecologic oncology team has reviewed the pathology, because the type of surgeon and the completeness of staging affect what comes next. Waiting for that review, sometimes a few weeks, is a deliberate step, not a delay caused by neglect. Ask your team what the wait is for and what would change the plan.

Ovarian cancer treatment by stage: what stage 2 and stage 3 ovarian cancer treatment usually involves

Once cancer has moved beyond the ovary, the plan almost always has two halves: an operation aimed at removing every visible deposit, and chemotherapy to reach the microscopic cells no surgeon can see. Stage 3 ovarian cancer treatment is the setting most people picture when they think of this disease, because stage 3 is the most common stage at diagnosis for epithelial cancers, according to the National Cancer Institute.

The surgical goal has a specific name. Debulking, or cytoreductive surgery, means removing as much tumor as possible; “complete” or “optimal” debulking means no visible cancer, or only very small deposits, remain. Evidence summarized by the National Cancer Institute links the amount of cancer left after surgery to how people do afterward, which is why surgeons may remove parts of the bowel, the spleen or the peritoneal lining to reach that goal.

Chemotherapy for stage 2 and 3 disease is typically a combination of a platinum-based drug and a taxane, both given into a vein. For some people with stage 3 disease that has been fully debulked, part of the chemotherapy may be given directly into the abdominal cavity through a small port; your team will explain whether that is offered in your case and what the evidence shows for your situation.

Stage	Where the cancer is	Surgery usually aims to	Chemotherapy is usually
1	Ovary or tube only	Remove and stage; sometimes fertility-sparing	Considered only if higher-risk features
2	Within the pelvis	Remove all visible disease	Usually given after surgery
3	Abdominal lining or lymph nodes	Debulk to no visible disease	Standard, before or after surgery
4	Beyond the abdomen or inside organs	Debulk when feasible	Central; often started first

The table is a map, not a prescription. Two people with stage 3 disease can receive very different plans depending on grade, general health and how the cancer responds to its first weeks of treatment.

Stage 4 ovarian cancer treatment: what the plan looks like when it has spread to the liver or beyond

Stage 4 is the point where two questions people type into search engines collide: what happens when ovarian cancer reaches the liver, and what a diagnosis at this stage means for the future.

Take the liver question first, because the anatomy genuinely matters. Ovarian cancer that has settled on the surface of the liver is classed as stage 3, because it is still spread within the abdominal lining. Cancer that has grown inside the liver tissue, or spread to the lungs, distant lymph nodes or other organs, is stage 4. The National Cancer Institute’s staging description makes this distinction, and it changes what surgery can realistically achieve. Surface deposits can sometimes be removed during debulking; deposits inside the liver usually cannot.

The treatment plan at stage 4 still uses the same two tools. Chemotherapy becomes the central pillar and is often started before any operation, because widespread disease is hard to remove completely on the first attempt. If the cancer shrinks well, an interval debulking operation may follow. Targeted drugs that block blood-vessel growth or interfere with DNA repair in cancer cells may be added or used as maintenance, depending on the tumor’s genetic profile. When surgery is not possible, treatment focuses on controlling the disease and protecting quality of life for as long as possible.

On life expectancy: no honest article can give you a number that applies to you. Registry statistics describe groups of people diagnosed years ago, before several current treatments existed, and they are averages across very different situations. Your own outlook depends on how the cancer responds to its first treatment, whether debulking is possible, the cancer’s genetic features and your overall health. The right person to interpret the statistics for your situation is your oncologist, who can see all of those variables at once. Asking them directly is not morbid; it is how people make plans.

What actually happens during debulking surgery for ovarian cancer

Debulking surgery for ovarian cancer is a long operation, and knowing why helps make the recovery period make sense.

It begins with a vertical incision down the middle of the abdomen, long enough for the surgeon to see and reach every surface where floating cancer cells could have landed. The first minutes are exploratory. The surgeon runs their hands over the peritoneum, the bowel, the diaphragm and the liver surface, and the picture from the scans is checked against what is really there.

Then the removal begins. The ovaries, fallopian tubes and uterus come out, along with the omentum. Peritoneal surfaces with cancer deposits are stripped. Lymph nodes in the pelvis and along the aorta may be removed. Where cancer has grown into the outer wall of the bowel, a segment of intestine may be removed and the ends rejoined; occasionally a temporary stoma (an opening on the abdomen for waste, closed in a later operation) is needed, and a good team will discuss that possibility beforehand rather than after. The spleen or part of the diaphragm lining may also be taken if disease sits there.

Every removed piece goes to the pathologist, whose report, usually available within a week or two, sets the final stage and grade.

Risks are those of any major abdominal operation: bleeding, infection, blood clots in the legs or lungs, injury to bowel or bladder, and problems related to anesthesia. Longer, more extensive operations carry more of each. Alternatives, when surgery is judged too risky or unlikely to remove enough disease, include chemotherapy alone or a smaller diagnostic procedure. The decision about how extensive to be, and whether to operate at all, rests with a gynecologic oncologist, a surgeon trained specifically in cancers of the female reproductive system. Mayo Clinic’s overview notes that this specialist involvement is a standard part of planning.

How chemotherapy for ovarian cancer works, and what the typical timeline looks like

Chemotherapy works because cancer cells divide faster and repair themselves less well than most healthy cells. The two drug classes used most in ovarian cancer attack this weakness from different angles. Platinum-based drugs bind to DNA and stop cancer cells copying it accurately. Taxanes jam the internal scaffolding that a cell needs to pull itself apart during division. Used together, they hit the same target from two directions.

The drugs are usually given into a vein, either through a cannula in the arm or through a small device placed under the skin of the chest for repeated access. Each treatment day is followed by a rest period so that healthy tissues, particularly blood-forming cells in the bone marrow, can recover. One treatment plus its rest period is called a cycle.

According to the NHS, chemotherapy for ovarian cancer is commonly planned as around six cycles, with each cycle lasting about three weeks, meaning the whole course typically stretches over four to five months. When chemotherapy is given before surgery, the NHS describes a common pattern of three cycles, then the operation, then the remaining cycles. These are typical ranges from a national guideline, not promises; cycles can be delayed if blood counts have not recovered, and the total number is decided by the treating oncologist.

Side effects follow from the mechanism. Because bone marrow cells divide quickly, infection risk rises and tiredness is common. Hair follicles divide quickly too, so hair loss is frequent with taxanes. Platinum drugs can affect the nerves in the hands and feet, causing tingling or numbness that your team will ask about at each visit, and can affect hearing and kidney function, which is why blood tests precede each cycle. Anti-nausea medicines have improved this experience considerably compared with earlier decades. Your team will explain the specific drugs, their expected effects and how they will monitor you; this article deliberately does not describe individual regimens.

Surgery first or chemotherapy before surgery for ovarian cancer? How the order is decided

This is the decision people find hardest to understand, because it seems to reverse the intuitive order of “take it out, then mop up.” The logic is worth laying out.

The traditional sequence is primary debulking surgery followed by chemotherapy. It suits people whose scans suggest the cancer can be removed completely, or nearly so, in one operation, and who are fit enough for a long anesthetic.

The alternative is neoadjuvant chemotherapy, meaning chemotherapy given before surgery, followed by interval debulking surgery partway through the course. The NHS and the National Cancer Institute both describe this as an accepted approach when disease is too widespread to remove fully at the outset, or when a person’s general health makes an immediate major operation unwise. The idea is simple: shrink the deposits first, so that when the surgeon operates, complete removal becomes achievable with a shorter, less extensive procedure.

What does the evidence say about which order is better? Randomized trials summarized in the National Cancer Institute’s treatment summary have found broadly similar long-term outcomes between the two sequences for people with advanced disease, with fewer surgical complications in the chemotherapy-first group. Those trials have been debated, partly over how thorough the surgery was, and specialist opinion still differs on how often chemotherapy should go first. That is why teams look at the individual: the volume and location of disease on imaging, whether a laparoscopy (a camera inspection through small incisions) suggests complete removal is realistic, and how well the person would tolerate surgery.

What this means for you is that neither order is a signal of how serious your situation is compared with someone else’s. Chemotherapy first is a strategy, not a downgrade. If your team recommends one sequence, ask what they saw on the scans that led them there, and what would prompt them to change course.

Ovarian cancer maintenance therapy: what happens after chemotherapy ends

For many people, the end of chemotherapy is not the end of treatment. Ovarian cancer maintenance therapy means continuing a lower-intensity treatment after the main course to keep the cancer from returning for as long as possible. It is a relatively recent addition to the pathway and one of the areas where planning has changed most.

Two classes of drugs are used. PARP inhibitors are tablets that block an enzyme cancer cells use to repair damaged DNA. Cancers with faults in the BRCA genes, or with a broader pattern called homologous recombination deficiency, already struggle to repair DNA; blocking PARP as well overwhelms them while healthy cells, which have backup systems, cope better. This is why your tumor and sometimes your blood will be tested for these genetic features early in treatment. The results shape whether maintenance is offered and which kind.

The second class, anti-angiogenic drugs such as bevacizumab, blocks the signal that tumors send out to grow new blood vessels. Starving a tumor of its supply lines slows regrowth. These are given by infusion and may be started alongside chemotherapy and continued afterward.

Maintenance is usually planned for a defined period rather than indefinitely, with regular reviews. Side effects differ from chemotherapy: PARP inhibitors commonly cause tiredness, nausea and lowered blood counts; anti-angiogenic drugs can raise blood pressure and, less commonly, affect wound healing or the bowel. Your team will monitor for these.

Whether maintenance is right for you depends on your cancer’s genetic profile, how it responded to chemotherapy, your stage and your other health conditions. The National Cancer Institute’s treatment summary describes these therapies as options for particular groups rather than for everyone. Starting, continuing or stopping any of them is a decision for the prescribing oncologist, weighed against your own priorities.

What the days and weeks after ovarian cancer treatment usually look like

Recovery has a rhythm, and knowing it in advance is calming.

After debulking surgery, the NHS describes a hospital stay of a few days for most people, longer if the operation involved the bowel or if complications arise. The first day or two are about pain control, breathing exercises to keep the lungs clear, and getting out of bed early to reduce the risk of blood clots. A catheter and sometimes a drain are removed as things settle. Eating restarts gradually; the bowel is slow to wake after abdominal surgery, and gas pain is common in the first days.

At home, expect several weeks before energy returns to something familiar. Mayo Clinic’s overview describes full recovery from major gynecologic surgery in terms of weeks, and heavy lifting is usually restricted for a similar period to protect the wound. Numbness around the scar can last months. If both ovaries were removed before menopause, hot flushes and mood changes may begin quickly, and your team can discuss ways to manage them.

Chemotherapy has its own cycle-shaped pattern. The days immediately after an infusion often bring the most nausea and tiredness; blood counts usually reach their lowest point around a week to ten days later, which is when infection risk peaks; then energy climbs back toward the next cycle. People often describe learning the shape of their own three weeks by the second cycle and planning around it.

The pathology report from surgery typically arrives within one to two weeks, and the team meeting that follows sets the final plan. Follow-up after treatment ends usually involves regular appointments, sometimes with CA-125 blood tests and scans if symptoms appear. The NHS notes that the schedule of follow-up varies and is set by the treating team.

If ovarian cancer comes back: how many times can you have chemotherapy?

Recurrence is a real possibility for people diagnosed at stage 3 or 4, and planning for it is part of honest care rather than pessimism. The question people most often ask is how many times chemotherapy can be repeated. The answer has more to do with timing than with a fixed count.

Oncologists group recurrences by how long after platinum-based chemotherapy they occur. The National Cancer Institute’s summary uses a threshold of about six months. Cancer that returns more than six months after finishing platinum treatment is described as platinum-sensitive, meaning it is likely to respond to platinum-based drugs again, and a similar combination may be offered. Cancer returning within six months, or growing during treatment, is called platinum-resistant, and different drugs are usually chosen because the cancer has shown it can survive platinum.

Each further course of chemotherapy is a separate decision. It weighs the length of the gap since the last course, how well the cancer responded before, side effects still lingering from earlier treatment (nerve damage from platinum drugs, for example, can accumulate), overall fitness and, above all, what the person wants from treatment at that point. Some people receive several courses over many years; others, after discussion, choose to focus on symptom control. There is no rule that sets a maximum number.

Surgery can sometimes be considered again for a recurrence, particularly when a single site has come back after a long disease-free interval, though this is assessed case by case. Maintenance drugs, targeted therapies and clinical trials also form part of the conversation at recurrence.

Follow-up appointments after initial treatment exist partly so that recurrence is detected while options are widest. If you notice new bloating, pelvic pain, changes in bowel habit or reduced appetite between appointments, tell your team rather than waiting for the next scheduled visit.

What people often get wrong about ovarian cancer treatment

Some of the most persistent ideas about this cancer are half true, and half truths shape decisions badly.

“If they give chemotherapy first, it means surgery isn’t possible.” Not so. Chemotherapy before surgery is a planned strategy to make surgery more complete, described as standard by both the NHS and the National Cancer Institute. An interval operation usually follows.

“A normal CA-125 means the cancer is gone.” CA-125 is useful for following trends, but it is not raised in every ovarian cancer and can rise for unrelated reasons such as endometriosis or infection. Cleveland Clinic’s overview describes it as a monitoring tool, not a definitive test, which is why it is read alongside scans and symptoms.

“Stage 4 means treatment is only about comfort.” Treatment at stage 4 still uses chemotherapy, often surgery and targeted drugs, with the aim of controlling the disease for as long as possible. Comfort and disease control are pursued together, not as alternatives.

“Cancer on the liver is always the most advanced stage.” Deposits on the liver’s surface are stage 3; only spread into the liver tissue itself is stage 4. The difference matters for surgical planning.

“Genetic testing is only about my relatives.” Testing for BRCA and related changes does inform family members, but it also directly affects whether maintenance therapy with a PARP inhibitor is likely to help you.

“Survival statistics predict what will happen to me.” They describe past groups of people, many treated before current therapies existed. They are context, not prophecy.

“Supplements or special diets can replace or boost chemotherapy.” There is no reliable evidence that any supplement treats ovarian cancer, and some can interact with chemotherapy or affect bleeding around surgery. Tell your team about anything you take.

Questions to ask your care team about your treatment plan

A good consultation is a conversation, and preparing questions changes its shape. Bring someone with you if you can, and write down the answers; most people remember far less than they expect from these appointments.

• What is the stage, type and grade of my cancer, and how confident are you in each before surgery?
• Are you recommending surgery first or chemotherapy first, and what did you see on my scans that led to that choice?
• Who will perform the operation, and is a gynecologic oncologist involved in planning it?
• What exactly do you expect to remove, and is there any chance I will need a stoma or bowel surgery?
• If I hope to have children, is fertility-sparing surgery an option for me, and what are the trade-offs?
• How many chemotherapy cycles are planned, and what would cause you to change the number or the drugs?
• Will my tumor be tested for BRCA and related genetic changes, and how would the results change my plan?
• Is maintenance therapy likely to be offered after chemotherapy, and for how long would it typically continue?
• What side effects should I expect from each part of treatment, and which ones should make me call you the same day?
• How will you monitor whether treatment is working, and how often will I be seen afterward?
• Are there clinical trials I might be eligible for at any point in this pathway?
• If the cancer returns, how would you approach it, and what would you want to know at that time?
• Who is my point of contact between appointments, and how do I reach them out of hours?

You are entitled to ask the same question more than once, and to ask for time before agreeing to a plan. The team expects both.

When to call your doctor during or after ovarian cancer treatment

Treatment for ovarian cancer lowers your body’s reserves, and some problems need attention within hours rather than at the next appointment. Every chemotherapy unit gives out a contact number for exactly this reason; keep it somewhere you will find it at two in the morning.

Call your care team the same day, or go to emergency care, if you notice any of the following:

• A fever, or feeling shivery, hot or unwell during chemotherapy, even without a measured temperature. The NHS and Cleveland Clinic both stress that infection during chemotherapy can become serious quickly because white blood cell counts are low.
• New or worsening pain in the abdomen, especially with a swollen, hard belly, vomiting or an inability to pass stool or wind, which can signal a bowel blockage.
• Sudden breathlessness, chest pain, or a swollen, painful calf, which may indicate a blood clot; the risk is raised after abdominal surgery and during cancer treatment.
• Redness, spreading warmth, pus or a foul smell from the surgical wound, or the wound edges separating.
• Heavy or persistent bleeding from the vagina or elsewhere, or unexplained bruising.
• Severe diarrhea or vomiting that stops you keeping fluids down, or signs of dehydration such as passing very little urine.
• Numbness or tingling in the hands or feet that is worsening or affecting how you walk or grip.
• A sudden severe headache, confusion or new weakness on one side of the body.

Between treatments, contact the team promptly about new bloating, loss of appetite, pelvic pressure or a change in bowel habit lasting more than a couple of weeks; these are the symptoms most often linked to the disease returning, and reporting them early keeps options open. None of this is overreacting. Teams would far rather hear from you about a fever that turns out to be nothing than not hear from you about one that was not.

Frequently asked questions

What is the life expectancy of a woman with stage 4 ovarian cancer?

No single figure applies to an individual, and reputable teams will not give one without knowing far more than the stage. Registry statistics describe groups diagnosed years ago, before several current treatments existed. Your outlook depends on how the cancer responds to first treatment, whether debulking surgery is possible, the tumor’s genetic features and your general health. Your oncologist can interpret the statistics in light of all of these; asking directly is reasonable.

How many times can you have chemotherapy for ovarian cancer?

There is no fixed maximum. Each course is a separate decision based on how long since the last one, how the cancer responded before, lingering side effects such as nerve damage, overall fitness and your own wishes. The National Cancer Institute describes recurrence more than about six months after platinum chemotherapy as platinum-sensitive, often allowing platinum drugs again; earlier recurrence usually prompts different drugs. Some people receive several courses over many years.

Can ovarian cancer be treated successfully, or is it always terminal?

Outcomes vary enormously by stage, type and grade, and neither extreme is accurate. Early-stage disease confined to the ovary is often controlled long-term with surgery, sometimes without chemotherapy. Advanced disease is treated with the aim of removing visible cancer, controlling what remains and prolonging good-quality life, and many people live for years with periods of treatment and remission. Your team can explain what is realistic in your specific situation.

What is the survival rate for ovarian cancer that has spread to the liver?

It depends on where in the liver the cancer sits. Deposits on the liver’s surface count as stage 3 and can sometimes be removed during debulking surgery; spread into the liver tissue itself is stage 4 and is treated mainly with chemotherapy and targeted drugs. Published survival figures are group averages from cancer registries and cannot predict an individual’s course. Ask your oncologist to explain how the pattern of spread affects your options.

What does stage 3 ovarian cancer treatment usually involve?

Stage 3 treatment almost always combines debulking surgery, aimed at removing all visible cancer from the abdomen, with platinum-based chemotherapy. The order varies: surgery may come first if scans suggest complete removal is achievable, or chemotherapy may be given first to shrink the disease before an interval operation. Maintenance therapy with a PARP inhibitor or anti-angiogenic drug may follow, depending on the tumor’s genetic profile and response to treatment.

Why is chemotherapy sometimes given before surgery for ovarian cancer?

Chemotherapy before surgery, called neoadjuvant chemotherapy, is used when the cancer is too widespread to remove completely in one operation or when a person is not well enough for immediate major surgery. Shrinking the deposits first makes complete removal more achievable at the interval operation and can reduce surgical complications. Randomized trials summarized by the National Cancer Institute found broadly similar long-term outcomes between the two sequences for advanced disease.

What is debulking surgery for ovarian cancer?

Debulking, or cytoreductive surgery, is an operation to remove as much visible cancer as possible from the abdomen. It usually includes removing the ovaries, fallopian tubes, uterus and omentum, stripping affected peritoneal surfaces and sampling lymph nodes; sometimes parts of the bowel or spleen are removed. Surgeons aim for no visible disease remaining, because the amount left behind is linked to how people do afterward. A gynecologic oncologist typically performs it.

What is ovarian cancer maintenance therapy and who gets it?

Maintenance therapy is treatment continued after chemotherapy to delay the cancer’s return. The main options are PARP inhibitors, tablets that block a DNA-repair enzyme and work particularly well in cancers with BRCA or related faults, and anti-angiogenic drugs that block tumor blood-vessel growth. It is offered to specific groups based on genetic testing, stage and response to chemotherapy, usually for a defined period, and the decision rests with the prescribing oncologist.

Is genetic testing part of ovarian cancer treatment planning?

Yes, for most people with epithelial ovarian cancer. The tumor, and often a blood sample, is tested for BRCA gene faults and a wider DNA-repair pattern called homologous recombination deficiency. The results influence whether PARP inhibitor maintenance therapy is likely to help. They also matter for blood relatives, who may be offered testing and risk-reducing options. Ask your team when testing will happen and how the results will be shared with you.

How long is recovery after ovarian cancer surgery?

The NHS describes a hospital stay of a few days after ovarian cancer surgery, longer if the bowel was involved or complications occur. At home, Mayo Clinic describes recovery from major gynecologic surgery in terms of weeks, with lifting restrictions during that period. Chemotherapy, if planned afterward, usually begins once the wound has healed and the team is satisfied with your recovery. Your surgeon will give a timeline based on your specific operation.

References

• NHS: Ovarian cancer – Treatment
• Cleveland Clinic: Ovarian Cancer
• MedlinePlus: Ovarian Cancer

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.